<html>
<head>
<meta charset='utf-8'>
<title>Daily Biotech & Science Report (2025-11-02)</title>
<style>

             body { font-family: Arial, sans-serif; margin: 20px; background-color: #f4f4f4; }
             .container { max-width: 800px; margin: auto; background: #fff; padding: 20px; }
             h1, h2, h3 { color: #333; }
             .news-item, .paper-item { border: 1px solid #ddd; padding: 15px; margin-bottom: 15px; border-radius: 5px; background: #fafafa; }
             .source-date { font-size: 0.9em; color: #666; }
             a { color: #1a0dab; text-decoration: none; }
             a:hover { text-decoration: underline; }
         
</style>
</head>
<body>
<div class='container'>
<h1>Daily Biotech & Science Report (2025-11-02)</h1>
<h2>Biotech Industry & Market News</h2>
<div class='news-item'>
<h3>Bird Flu’s Human Risk Spurs Phage Therapy Research</h3>
<p class='source-date'><em>GEN – Genetic Engineering and Biotechnology News • 2025-11-01</em></p>
<p>Highly pathogenic avian influenza A (H5N1, commonly known as HPAI or bird flu) is a formidable worldwide public health concern. With approximately a 100% mortality rate, the World Organization for Animal Health […] The post Bird Flu’s Human Risk Spurs Phage Therapy Research appeared first on GEN ...</p>
<p><a href='https://www.genengnews.com/topics/infectious-diseases/bird-flus-human-risk-spurs-phage-therapy-research/' target='_blank'>Read more</a></p>
</div>
<div class='news-item'>
<h3>Top 20 Drugs Heading for the Patent Cliff, 2026-2029</h3>
<p class='source-date'><em>GEN – Genetic Engineering and Biotechnology News • 2025-11-01</em></p>
<p>Last year, these treatments accounted for 75% of the $236B in annual sales set to vanish with the loss of exclusivity. The post Top 20 Drugs Heading for the Patent Cliff, 2026-2029 appeared first on GEN - Genetic Engineering and Biotechnology News.</p>
<p><a href='https://www.genengnews.com/topics/drug-discovery/top-20-drugs-heading-for-the-patent-cliff-2026-2029/' target='_blank'>Read more</a></p>
</div>
<div class='news-item'>
<h3>Biopharma Embraces Synthetic Biology</h3>
<p class='source-date'><em>GEN – Genetic Engineering and Biotechnology News • 2025-11-01</em></p>
<p>Synthetic Biology has begun to drive innovation in biopharmaceuticals. GEN spoke with four companies to explore how they are leveraging synthetic biology in their work. The post Biopharma Embraces Synthetic Biology appeared first on GEN - Genetic Engineering and Biotechnology News.</p>
<p><a href='https://www.genengnews.com/topics/drug-discovery/biopharma-embraces-synthetic-biology/' target='_blank'>Read more</a></p>
</div>
<div class='news-item'>
<h3>Mass Spec Brings Multiomics Into Sharper Focus</h3>
<p class='source-date'><em>GEN – Genetic Engineering and Biotechnology News • 2025-11-01</em></p>
<p>Improvements in sensitivity, specificity, and accurate quantitation allow researchers to glean valuable information from hundreds of samples in record time. The post Mass Spec Brings Multiomics Into Sharper Focus appeared first on GEN - Genetic Engineering and Biotechnology News.</p>
<p><a href='https://www.genengnews.com/topics/omics/mass-spec-brings-multiomics-into-sharper-focus/' target='_blank'>Read more</a></p>
</div>
<div class='news-item'>
<h3>AI Models Enhance the Drug Discovery Portfolio</h3>
<p class='source-date'><em>GEN – Genetic Engineering and Biotechnology News • 2025-11-01</em></p>
<p>From predicting small molecule binding affinity to cellular reprogramming, large-scale biological data combined with new model architectures continue to propel the AI revolution forward. Time will tell if rising computational power will lift the boat of therapeutic potential. The post AI Models E...</p>
<p><a href='https://www.genengnews.com/topics/artificial-intelligence/ai-models-enhance-the-drug-discovery-portfolio/' target='_blank'>Read more</a></p>
</div>
<div class='news-item'>
<h3>Novo makes a play for Metsera; This week’s other big deal; Earnings in full swing; and more</h3>
<p class='source-date'><em>Endpoints News • 2025-11-01</em></p>
<p>Welcome back to Endpoints Weekly, and welcome to November. This week kicked off with quarterly earnings results from a handful of companies, including Eli Lilly, Merck, Novartis and Bristol Myers Squibb. Then on Thursday, Novo ...</p>
<p><a href='https://endpoints.news/novo-makes-a-play-for-metsera-this-weeks-other-big-deal-earnings-in-full-swing-and-more/' target='_blank'>Read more</a></p>
</div>
<h2>Microbiome & Antimicrobials News</h2>
<div class='news-item'>
<h3>Methanobrevibacter smithii</h3>
<p class='source-date'><em>Trends in Microbiology • 2025-10-31</em></p>
<p>Methanobrevibacter smithii is one of the most prevalent and worldwide distributed archaea in the human gut. M. smithii is a strict anaerobe that obtains its energy through methanogenesis. In culture, it reduces CO2 to methane (CH4) using H2 as electron donor (i.e., CO2-reducing hydrogenotrophic m...</p>
<p><a href='https://www.cell.com/trends/microbiology/fulltext/S0966-842X(25)00296-3?rss=yes' target='_blank'>Read more</a></p>
</div>
<hr>
<h2>Scientific Papers</h2>
<h3>Biotech & Microbiome Focus Papers</h3>
<p>No recent papers on Biotech & Microbiome Focus available today.</p>
<h3>Synthetic & Molecular Biology Papers</h3>
<p>No recent papers on Synthetic & Molecular Biology available today.</p>
<h3>Bacteriophage Research Papers</h3>
<p>No recent papers on Bacteriophage Research available today.</p>
<h3>Skin Microbiome & Disease Papers</h3>
<p>No recent papers on Skin Microbiome & Disease available today.</p>
<hr>
<p><em>Report generated on 2025-11-02</em></p>
</div>
</body>
</html>